Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
Cell Rep Med
; 5(7): 101655, 2024 Jul 16.
Article
em En
| MEDLINE
| ID: mdl-39019010
ABSTRACT
Yellow fever virus (YFV) is endemic in >40 countries and causes viscerotropic disease with up to 20%-60% mortality. Successful live-attenuated yellow fever (YF) vaccines were developed in the mid-1930s, but their use is restricted or formally contraindicated in vulnerable populations including infants, the elderly, and people with compromised immune systems. In these studies, we describe the development of a next-generation hydrogen peroxide-inactivated YF vaccine and determine immune correlates of protection based on log neutralizing index (LNI) and neutralizing titer-50% (NT50) studies. In addition, we compare neutralizing antibody responses and protective efficacy of hydrogen peroxide-inactivated YF vaccine candidates to live-attenuated YFV-17D (YF-VAX) in a rhesus macaque model of viscerotropic YF. Our results indicate that an optimized, inactivated YF vaccine elicits protective antibody responses that prevent viral dissemination and lethal infection in rhesus macaques and may be a suitable alternative for vaccinating vulnerable populations who are not eligible to receive replicating live-attenuated YF vaccines.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Febre Amarela
/
Vírus da Febre Amarela
/
Vacinas de Produtos Inativados
/
Vacina contra Febre Amarela
/
Modelos Animais de Doenças
/
Anticorpos Neutralizantes
/
Peróxido de Hidrogênio
/
Macaca mulatta
/
Anticorpos Antivirais
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cell Rep Med
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos